Zeynep Alp Ünkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zeynep Alp Ünkar has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Akan Yaman
Department of Pediatrics, Division of Neonatalogy, Faculty of Medicine, Nisantasi University, İstanbul, Türkiye
4 shared publications - Ibrahim Kandemir
Department of Pediatrics, Istanbul Health and Technology University, Istanbul 34275, Turkey
4 shared publications - Asli Memisoglu
Marmara University
3 shared publications - Hulya Ozdemir
Marmara University
3 shared publications - Mehmet Tolga Köle
Ankara Etlik Şehir Hastanesi
3 shared publications - Sinem Gülcan Kersin
Marmara University
3 shared publications
Latest Publications
- Open Access
- 15 October 2024
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 35 (1)
Early Period Survival and Neurologic Prognosis in Newborns with Perinatal Asphyxia: A Tertiary Center Experience and a Mortality Chart
Background: Clinicians require more data regarding mortality and brain damage risk factors in perinatal asphyxia. Objectives: To assess early term outcomes and identify mortality risk factors in perinatal asphyxia. Methods: This study was conducted in a referral-center tertiary intensive care unit in Istanbul, Turkey, between 2016 and 2023. We included all patients who underwent therapeutic hypothermia treatment due to perinatal asphyxia. We recorded laboratory follow-up data, magnetic resonance imaging (MRI) findings, amplitude-integrated electroencephalograms (aEEG) results, mortality, and clinical outcomes. Both conventional frequentist statistical methods and Bayesian methods were used for analysis. Results: A total of 164 patients were included in the study, with an overall mortality rate of 9.8%. Risk factors for mortality included LDH, troponin I, INR, lactate, 2nd day creatinine, voltage anomalies, seizures, and male gender, as well as APGAR scores. A basic chart for mortality prediction was developed. The Sarnat score showed strong evidence, and APGAR 1 showed anecdotal evidence for association with brain damage, although brain damage was independent of laboratory results and other clinical findings, based on moderate and anecdotal evidence from Bayesian calculations. Cranial MRI findings revealed profound damage in 14.8% of Sarnat 1, 21.8% of Sarnat 2, and 50% of Sarnat 3 patients. Conclusions: This study presents prognostic factors for survival and brain damage in perinatal asphyxia. We recommend obtaining cranial MRI for all patients diagnosed with asphyxia, as most laboratory tests were independent of brain damage. Given that profound brain damage can occur even in Sarnat stage I patients, we emphasize the importance of therapeutic hypothermia for these patients.
- 15 October 2024
- Published by Brieflands in Iranian Journal of Pediatrics
- Vol. 35 (1)
Open AccessEarly Period Survival and Neurologic Prognosis in Newborns with Perinatal Asphyxia: A Tertiary Center Experience and a Mortality Chart
Background: Clinicians require more data regarding mortality and brain damage risk factors in perinatal asphyxia. Objectives: To assess early term outcomes and identify mortality risk factors in perinatal asphyxia. Methods: This study was conducted in a referral-center tertiary intensive care unit in Istanbul, Turkey, between 2016 and 2023. We included all patients who underwent therapeutic hypothermia treatment due to perinatal asphyxia. We recorded laboratory follow-up data, magnetic resonance imaging (MRI) findings, amplitude-integrated electroencephalograms (aEEG) results, mortality, and clinical outcomes. Both conventional frequentist statistical methods and Bayesian methods were used for analysis. Results: A total of 164 patients were included in the study, with an overall mortality rate of 9.8%. Risk factors for mortality included LDH, troponin I, INR, lactate, 2nd day creatinine, voltage anomalies, seizures, and male gender, as well as APGAR scores. A basic chart for mortality prediction was developed. The Sarnat score showed strong evidence, and APGAR 1 showed anecdotal evidence for association with brain damage, although brain damage was independent of laboratory results and other clinical findings, based on moderate and anecdotal evidence from Bayesian calculations. Cranial MRI findings revealed profound damage in 14.8% of Sarnat 1, 21.8% of Sarnat 2, and 50% of Sarnat 3 patients. Conclusions: This study presents prognostic factors for survival and brain damage in perinatal asphyxia. We recommend obtaining cranial MRI for all patients diagnosed with asphyxia, as most laboratory tests were independent of brain damage. Given that profound brain damage can occur even in Sarnat stage I patients, we emphasize the importance of therapeutic hypothermia for these patients.
- Open Access
- 29 August 2024
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 25 (3) , 152-158
Perinatal outcomes of antenatally diagnosed omphalocele and gastroschisis: a survey from a university hospital
Perinatal outcomes of antenatally diagnosed omphalocele and gastroschisis: a survey from a university hospital - Journal of the Turkish-German Gynecological Association
- 29 August 2024
- Published by Galenos Yayinevi in Journal of the Turkish-German Gynecological Association
- Vol. 25 (3) , 152-158
Open AccessPerinatal outcomes of antenatally diagnosed omphalocele and gastroschisis: a survey from a university hospital
Perinatal outcomes of antenatally diagnosed omphalocele and gastroschisis: a survey from a university hospital - Journal of the Turkish-German Gynecological Association
- Open Access
- 30 January 2024
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 4 (1) , 1-6
Is medical therapy succesful in hemodynamically significant patent ductus treatment in term newborns?
Aim: To investigate the clinical success of medical patent ductus arteriosus closure treatment for hemodynamically significant patent ductus arteriosus in term babies. Methods: Our study included patients treated in two neonatal intensive care units with hemodynamically significant patent ductus arteriosus after the 3rd postnatal day and administered medical patent ductus arteriosus closure treatment (ibuprofen and paracetamol) at the discretion of the pediatric cardiologists while awaiting referral for surgical closure treatment. Our retrospective analysis included anthropometric measurements at birth, the day treatment started postnatally, and other existing clinical conditions that might influence the prognosis of patent ductus arteriosus. Then, treatment success was evaluated by echocardiographic results. Results: We included all ten patients diagnosed with hemodynamically significant patent ductus arteriosus and administered medical treatment with a mean gestational age at birth of 38.4 ± 1.21 weeks, and median birth weight of 3125 grams (3005-3200). We started medical closure treatment at mean postnatal 11.6 ± 4.9 days with ibuprofen (70%, n=7) or paracetamol (30%, n=3). 40% (n=4) of the infants had complete closure, 20% (n=2) became asymptomatic, and 10% (n=1) underwent surgical ligation. 30% (n=3) of patients died due to different complications during surgical preparation. As we defined treatment success as complete or partial closure and compared paracetamol and ibuprofen success, there was no statistically significant difference between them (p=0.5). Conclusion: Medical closure treatment might be effective in the presence of hemodynamically significant patent ductus arteriosus in term infants. There was no statistical superiority of paracetamol or ibuprofen treatments over each other in terms of treatment success.
- 30 January 2024
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 4 (1) , 1-6
Open AccessIs medical therapy succesful in hemodynamically significant patent ductus treatment in term newborns?
Aim: To investigate the clinical success of medical patent ductus arteriosus closure treatment for hemodynamically significant patent ductus arteriosus in term babies. Methods: Our study included patients treated in two neonatal intensive care units with hemodynamically significant patent ductus arteriosus after the 3rd postnatal day and administered medical patent ductus arteriosus closure treatment (ibuprofen and paracetamol) at the discretion of the pediatric cardiologists while awaiting referral for surgical closure treatment. Our retrospective analysis included anthropometric measurements at birth, the day treatment started postnatally, and other existing clinical conditions that might influence the prognosis of patent ductus arteriosus. Then, treatment success was evaluated by echocardiographic results. Results: We included all ten patients diagnosed with hemodynamically significant patent ductus arteriosus and administered medical treatment with a mean gestational age at birth of 38.4 ± 1.21 weeks, and median birth weight of 3125 grams (3005-3200). We started medical closure treatment at mean postnatal 11.6 ± 4.9 days with ibuprofen (70%, n=7) or paracetamol (30%, n=3). 40% (n=4) of the infants had complete closure, 20% (n=2) became asymptomatic, and 10% (n=1) underwent surgical ligation. 30% (n=3) of patients died due to different complications during surgical preparation. As we defined treatment success as complete or partial closure and compared paracetamol and ibuprofen success, there was no statistically significant difference between them (p=0.5). Conclusion: Medical closure treatment might be effective in the presence of hemodynamically significant patent ductus arteriosus in term infants. There was no statistical superiority of paracetamol or ibuprofen treatments over each other in terms of treatment success.
- Open Access
- 30 January 2024
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 4 (1) , 1-6
Is medical therapy succesful in hemodynamically significant patent ductus treatment in term newborns?
Aim: To investigate the clinical success of medical patent ductus arteriosus closure treatment for hemodynamically significant patent ductus arteriosus in term babies. Methods: Our study included patients treated in two neonatal intensive care units with hemodynamically significant patent ductus arteriosus after the 3rd postnatal day and administered medical patent ductus arteriosus closure treatment (ibuprofen and paracetamol) at the discretion of the pediatric cardiologists while awaiting referral for surgical closure treatment. Our retrospective analysis included anthropometric measurements at birth, the day treatment started postnatally, and other existing clinical conditions that might influence the prognosis of patent ductus arteriosus. Then, treatment success was evaluated by echocardiographic results. Results: We included all ten patients diagnosed with hemodynamically significant patent ductus arteriosus and administered medical treatment with a mean gestational age at birth of 38.4 ± 1.21 weeks, and median birth weight of 3125 grams (3005-3200). We started medical closure treatment at mean postnatal 11.6 ± 4.9 days with ibuprofen (70%, n=7) or paracetamol (30%, n=3). 40% (n=4) of the infants had complete closure, 20% (n=2) became asymptomatic, and 10% (n=1) underwent surgical ligation. 30% (n=3) of patients died due to different complications during surgical preparation. As we defined treatment success as complete or partial closure and compared paracetamol and ibuprofen success, there was no statistically significant difference between them (p=0.5). Conclusion: Medical closure treatment might be effective in the presence of hemodynamically significant patent ductus arteriosus in term infants. There was no statistical superiority of paracetamol or ibuprofen treatments over each other in terms of treatment success.
- 30 January 2024
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 4 (1) , 1-6
Open AccessIs medical therapy succesful in hemodynamically significant patent ductus treatment in term newborns?
Aim: To investigate the clinical success of medical patent ductus arteriosus closure treatment for hemodynamically significant patent ductus arteriosus in term babies. Methods: Our study included patients treated in two neonatal intensive care units with hemodynamically significant patent ductus arteriosus after the 3rd postnatal day and administered medical patent ductus arteriosus closure treatment (ibuprofen and paracetamol) at the discretion of the pediatric cardiologists while awaiting referral for surgical closure treatment. Our retrospective analysis included anthropometric measurements at birth, the day treatment started postnatally, and other existing clinical conditions that might influence the prognosis of patent ductus arteriosus. Then, treatment success was evaluated by echocardiographic results. Results: We included all ten patients diagnosed with hemodynamically significant patent ductus arteriosus and administered medical treatment with a mean gestational age at birth of 38.4 ± 1.21 weeks, and median birth weight of 3125 grams (3005-3200). We started medical closure treatment at mean postnatal 11.6 ± 4.9 days with ibuprofen (70%, n=7) or paracetamol (30%, n=3). 40% (n=4) of the infants had complete closure, 20% (n=2) became asymptomatic, and 10% (n=1) underwent surgical ligation. 30% (n=3) of patients died due to different complications during surgical preparation. As we defined treatment success as complete or partial closure and compared paracetamol and ibuprofen success, there was no statistically significant difference between them (p=0.5). Conclusion: Medical closure treatment might be effective in the presence of hemodynamically significant patent ductus arteriosus in term infants. There was no statistical superiority of paracetamol or ibuprofen treatments over each other in terms of treatment success.
- 15 June 2023
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 8 (2) , 155-160
Early Clinical Outcomes of Congenital Diaphragmatic Hernia and Prognosis: A Retrospective Multicenter Study
- 15 June 2023
- Published by Galenos Yayinevi in Bagcilar Medical Bulletin
- Vol. 8 (2) , 155-160
Early Clinical Outcomes of Congenital Diaphragmatic Hernia and Prognosis: A Retrospective Multicenter Study
- Open Access
- 1 March 2023
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 58 (2) , 159-167
Evaluation of Short-Term Outcomes of Preterm Infants in 2 Periods: Vermont Oxford Network Results of a Developing Country’s Single- Center Level IIIC Neonatal Intensive Care Unit Experience
Objective: This study aimed to compare the short-term outcomes of infants from our level IIIC neonatal intensive care unit in 2 different periods. Materials and Methods: In this cohort study, data from preterm infants (≤29 weeks and birth weight <1500 g) registered in the Vermont Oxford Network system were divided into 2 periods, the first period between January 1, 2005, and December 31, 2009, and the second between January 1, 2010, and December 31, 2019. Results: There was no difference in the distribution of preterm infants according to their gestational age subgroups (P = .169). Although the survival rate increased significantly in the second period (48.1% vs. 64.3% (P < .001), there was no difference in terms of survival without morbidity (P = .480). The frequency of antenatal care (P < .001), antenatal maternal steroid use (P < .001), cesarean section (P = .025), and small for gestational age (P < .003) increased in the second period. Surfactant treatment in the delivery room (P < .003), neonatal intensive care unit (P < .001), and nasal continuous positive airway pressure use before intubation as a part of initial resuscitation (P < .001), nosocomial infections (P = .001), patent ductus arteriosus requiring medical treatment (P = .011), and necrotizing enterocolitis (P = .014) were significantly more common, but early neonatal sepsis (P = .002) and discharge home with only formula (P = .010) were less in the second period. Conclusion: Differences were noted in the prognosis and treatment choices of preterm infants in the same unit between 2 periods. The analysis of neonatal intensive care unit data, through rigorous methods, may provide opportunities for the development of quality improvement projects to improve the quality of health care in developing countries. Cite this article as: Yılmaz A, Kaya N, Alp Ünkar Z, et al. Evaluation of short-term outcomes of preterm infants in 2 periods: Vermont Oxford Network results of a developing country’s single-center level IIIC neonatal intensive care unit experience. Turk Arch Pediatr. 2023;58(2):159-167.
- 1 March 2023
- Published by Caleo in Turkish Archives of Pediatrics
- Vol. 58 (2) , 159-167
Open AccessEvaluation of Short-Term Outcomes of Preterm Infants in 2 Periods: Vermont Oxford Network Results of a Developing Country’s Single- Center Level IIIC Neonatal Intensive Care Unit Experience
Objective: This study aimed to compare the short-term outcomes of infants from our level IIIC neonatal intensive care unit in 2 different periods. Materials and Methods: In this cohort study, data from preterm infants (≤29 weeks and birth weight <1500 g) registered in the Vermont Oxford Network system were divided into 2 periods, the first period between January 1, 2005, and December 31, 2009, and the second between January 1, 2010, and December 31, 2019. Results: There was no difference in the distribution of preterm infants according to their gestational age subgroups (P = .169). Although the survival rate increased significantly in the second period (48.1% vs. 64.3% (P < .001), there was no difference in terms of survival without morbidity (P = .480). The frequency of antenatal care (P < .001), antenatal maternal steroid use (P < .001), cesarean section (P = .025), and small for gestational age (P < .003) increased in the second period. Surfactant treatment in the delivery room (P < .003), neonatal intensive care unit (P < .001), and nasal continuous positive airway pressure use before intubation as a part of initial resuscitation (P < .001), nosocomial infections (P = .001), patent ductus arteriosus requiring medical treatment (P = .011), and necrotizing enterocolitis (P = .014) were significantly more common, but early neonatal sepsis (P = .002) and discharge home with only formula (P = .010) were less in the second period. Conclusion: Differences were noted in the prognosis and treatment choices of preterm infants in the same unit between 2 periods. The analysis of neonatal intensive care unit data, through rigorous methods, may provide opportunities for the development of quality improvement projects to improve the quality of health care in developing countries. Cite this article as: Yılmaz A, Kaya N, Alp Ünkar Z, et al. Evaluation of short-term outcomes of preterm infants in 2 periods: Vermont Oxford Network results of a developing country’s single-center level IIIC neonatal intensive care unit experience. Turk Arch Pediatr. 2023;58(2):159-167.
- Open Access
- 12 October 2021
- Published by S. Karger AG in Molecular Syndromology
- Vol. 13 (2) , 108-116
The Methylation Status in the Chromosome 11p15.5 Region and Metabolic Disorders in Children with Syndromic and Nonsyndromic Intrauterine Growth Restriction
Loss of methylation (LoM) of the imprinting control region 1 (ICR1) in the chromosome 11p15.5 domain is detected in patients with Silver-Russell syndrome (SRS), characterized by asymmetric pre- and postnatal growth restriction, and typical craniofacial features. The patients with intrauterine growth restriction (IUGR) possess a high risk for adult metabolic problems. This study is aimed to investigate the methylation levels of the chromosome 11p15.5 region and metabolic problems in children with syndromic and nonsyndromic IUGR. Methylation analysis was performed for chromosome 11p15.5 in 49 patients (33 with suspected SRS and 16 nonsyndromic IUGR) with Netchine-Harbison clinical scoring (NHCS); uniparental disomy for chromosomes 6, 7, 14, and 20 was evaluated for those who were negative. LoM of ICR1 was detected in 14 of 33 suspected SRS patients with 3 or more criteria of NHCS, 5 had borderline LoM. Maternal uniparental disomy of the chromosomes 7 and 14 was found in 2 patients. The overall detection rate of SRS was 45.5%. While clinical findings were similar in patients with LoM and borderline LoM of ICR1, typical craniofacial findings were significantly less in the patients with normal methylation. Methylation patterns were not found to be impaired in the nonsyndromic IUGR group. Metabolic complications were evaluated in a total of 63 patients including 33 SRS-suspicious, 16 nonsyndromic IUGR, and 14 patients with 3M or SHORT syndrome. Increased rates of hypercalciuria, insulin resistance, and dyslipidemia were detected in patients with both syndromic and nonsyndromic IUGR. We would like to emphasize that detecting typical facial findings is effective in the diagnosis of SRS and paying attention to metabolic problems in the follow-up of patients with IUGR is recommended.
- 12 October 2021
- Published by S. Karger AG in Molecular Syndromology
- Vol. 13 (2) , 108-116
Open AccessThe Methylation Status in the Chromosome 11p15.5 Region and Metabolic Disorders in Children with Syndromic and Nonsyndromic Intrauterine Growth Restriction
Loss of methylation (LoM) of the imprinting control region 1 (ICR1) in the chromosome 11p15.5 domain is detected in patients with Silver-Russell syndrome (SRS), characterized by asymmetric pre- and postnatal growth restriction, and typical craniofacial features. The patients with intrauterine growth restriction (IUGR) possess a high risk for adult metabolic problems. This study is aimed to investigate the methylation levels of the chromosome 11p15.5 region and metabolic problems in children with syndromic and nonsyndromic IUGR. Methylation analysis was performed for chromosome 11p15.5 in 49 patients (33 with suspected SRS and 16 nonsyndromic IUGR) with Netchine-Harbison clinical scoring (NHCS); uniparental disomy for chromosomes 6, 7, 14, and 20 was evaluated for those who were negative. LoM of ICR1 was detected in 14 of 33 suspected SRS patients with 3 or more criteria of NHCS, 5 had borderline LoM. Maternal uniparental disomy of the chromosomes 7 and 14 was found in 2 patients. The overall detection rate of SRS was 45.5%. While clinical findings were similar in patients with LoM and borderline LoM of ICR1, typical craniofacial findings were significantly less in the patients with normal methylation. Methylation patterns were not found to be impaired in the nonsyndromic IUGR group. Metabolic complications were evaluated in a total of 63 patients including 33 SRS-suspicious, 16 nonsyndromic IUGR, and 14 patients with 3M or SHORT syndrome. Increased rates of hypercalciuria, insulin resistance, and dyslipidemia were detected in patients with both syndromic and nonsyndromic IUGR. We would like to emphasize that detecting typical facial findings is effective in the diagnosis of SRS and paying attention to metabolic problems in the follow-up of patients with IUGR is recommended.
- 1 March 2019
- Published by Galenos Yayinevi in The Journal of Pediatric Research
- Vol. 6 (1) , 7-11
Do We Have to Obtain Rebound Bilirubin Levels and What is the Optimal Time?
- 1 March 2019
- Published by Galenos Yayinevi in The Journal of Pediatric Research
- Vol. 6 (1) , 7-11
Do We Have to Obtain Rebound Bilirubin Levels and What is the Optimal Time?
- 1 May 2018
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 31 (6) , 693-695
Severe lactic acidosis in an extremely low birth weight infant due to thiamine deficiency
Background: In this case report, we present a preterm newborn with persistent lactic acidosis who received total parenteral nutrition (TPN) that lacked thiamine. Case presentation: A 28-week-old, 750 g female infant was born with an Apgar score of 8 at the 5th minute. Umbilical cord blood gas levels, including lactate level, were normal, and she was admitted to our neonatal intensive care unit (NICU). Achieving full enteral feeding was not possible due to gastric residues and abdominal distention, making the patient dependent on TPN during the first 2 weeks of life. An insidious increase in lactic acid levels and uncompensated metabolic acidosis were apparent from the 23rd day of life. Severe metabolic acidosis was persistent despite massive doses of bicarbonate. The acidosis resolved dramatically within 6 h when the patient was administered with thiamine. Conclusions: Although TPN is life saving in the NICU, meticulous attention must be paid to provide all essential macro- and micro-nutrients.
- 1 May 2018
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 31 (6) , 693-695
Severe lactic acidosis in an extremely low birth weight infant due to thiamine deficiency
Background: In this case report, we present a preterm newborn with persistent lactic acidosis who received total parenteral nutrition (TPN) that lacked thiamine. Case presentation: A 28-week-old, 750 g female infant was born with an Apgar score of 8 at the 5th minute. Umbilical cord blood gas levels, including lactate level, were normal, and she was admitted to our neonatal intensive care unit (NICU). Achieving full enteral feeding was not possible due to gastric residues and abdominal distention, making the patient dependent on TPN during the first 2 weeks of life. An insidious increase in lactic acid levels and uncompensated metabolic acidosis were apparent from the 23rd day of life. Severe metabolic acidosis was persistent despite massive doses of bicarbonate. The acidosis resolved dramatically within 6 h when the patient was administered with thiamine. Conclusions: Although TPN is life saving in the NICU, meticulous attention must be paid to provide all essential macro- and micro-nutrients.
- Open Access
- 1 January 2018
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 11 (1) , 130-132
A rare and emerging pathogen: Raoultella planticola identification based on 16S rRNA in an infant
- 1 January 2018
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 11 (1) , 130-132
Open AccessA rare and emerging pathogen: Raoultella planticola identification based on 16S rRNA in an infant